Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

EDP239

Small molecule · developed by Enanta Pharmaceuticals

Phase 1 Most advanced trial (none active)
ENTA Developer
1 Registered trials

What is EDP239?

EDP239 is a drug studied in hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Infectious disease
Developer
Enanta Pharmaceuticals, Inc (ENTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01856426 Phase 1 Hepatitis C Completed ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C

More from Enanta Pharmaceuticals

EDP-235 Phase 2 EDP-297 Phase 1 EDP-305 Phase 2 EDP-322 Phase 1 EDP-323 Phase 2 EDP-494 Phase 1 EDP-514 Phase 1 EDP-721 Phase 1 EDP-788 Phase 1 EDP-978 Phase 1 Zelicapavir Phase 2

Follow ENTA, the company behind EDP239

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.